



## **Cytokinetics to Present at Two Upcoming Investor Healthcare Conferences**

November 9, 2006 5:00 AM EST

SOUTH SAN FRANCISCO, Calif., November 9, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK - News) announced today that members of its management team are scheduled to present a corporate update at the following investor conferences:

- James H. Sabry, M.D., Ph.D., Chief Executive Officer, will present at The JMP Securities Healthcare Sector Focus Conference on November 16, 2006 at 1:30 PM Eastern at the Four Seasons Hotel in Boston, MA.
- Sharon Surrey-Barbari, Senior Vice President, Finance and Chief Financial Officer, will present at the 2006 Credit Suisse Annual Healthcare Conference on November 17, 2006, at 10:30 AM Mountain Standard at The Arizona Biltmore Resort in Phoenix, AZ.

Interested parties may access the live audio webcasts of these presentations and replay them by visiting the Cytokinetics website at [www.cytokinetics.com](http://www.cytokinetics.com). The webcast replay of these presentations will be archived on the Audio Presentations page in the Investors Center section of Cytokinetics' website until November 24, 2006. About Cytokinetics

Cytokinetics is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that specifically target the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Cytokinetics' focus on the cytoskeleton enables it to develop novel and potentially safer and more effective classes of drugs directed at treatments for cancer, cardiovascular disease and other diseases. Under a strategic alliance established in 2001, Cytokinetics and GlaxoSmithKline (GSK) are collaborating to develop and commercialize small molecule therapeutics targeting human mitotic kinesins for applications in the treatment of cancer and other diseases. Ispinesib (SB-715992), SB-743921 and GSK-923295 are being developed under the strategic alliance with GSK. GSK is conducting Phase II and Ib clinical trials for ispinesib and Cytokinetics is conducting a Phase I/II clinical trial of SB-743921 in non-Hodgkin's lymphoma. Cytokinetics' unpartnered cardiovascular disease program is the second program to leverage the company's expertise in cytoskeletal pharmacology. Cytokinetics recently completed a Phase I clinical trial with CK-1827452, a novel small molecule cardiac myosin activator, for the intravenous treatment of heart failure and also is advancing CK-1827452 as a potential drug candidate for the treatment of chronic heart failure via oral administration. Additional information about Cytokinetics can be obtained at <http://www.cytokinetics.com>.

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements relating to the potential benefits of Cytokinetics' drug candidates and potential drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to unexpected adverse side effects or inadequate therapeutic efficacy of Cytokinetics' drug candidates and other potential difficulties or delays in development, testing, regulatory approval, production and marketing of Cytokinetics' drug

candidates that could slow or prevent clinical development or product approval (including the risks relating to uncertainty of patent protection for Cytokinetics' intellectual property or trade secrets and Cytokinetics' ability to obtain additional financing if necessary and unanticipated research and development and other costs) the conduct of activities and continued funding under Cytokinetics' collaborations. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.